Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. (AIP) reporting person Nicholas B. Hawkins, Vice President and Chief Financial Officer, reported a sale of common stock on 09/09/2025 under a Rule 10b5-1 trading plan adopted June 4, 2025. The filing shows 3,660 shares were sold at a weighted average price of $8.6903, with the filing noting individual sale prices ranged from $8.51 to $8.83. After the reported sale, Mr. Hawkins beneficially owned 103,898 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/10/2025. The disclosure emphasizes the transaction was pursuant to a pre-established trading plan and offers to provide detailed per-price sale breakdowns upon request.
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported sales of company common stock under a 10b5-1 plan. On 09/08/2025 he sold 424 shares at $8.98 per share, and on 09/09/2025 he sold 2,278 shares at a weighted average price of $8.689 per share. After these transactions he beneficially owned 73,587 shares. The Form 4 states the sales were made pursuant to a trading plan adopted June 5, 2025, and provides a price range of $8.51 to $8.82 for the multiple trades comprising the weighted average.
Arteris, Inc. (AIP) insider Form 4 summary: The company's Chief Operating Officer, Laurent R. Moll, reported multiple sales of common stock in early September 2025 executed pursuant to a 10b5-1 trading plan adopted March 12, 2025. On 09/05/2025 she sold 4,698 shares at a weighted average price of $8.8045, reducing her beneficial ownership to 394,681 shares. On 09/08/2025 she sold 8,129 shares at a weighted average price of $8.7434, reducing beneficial ownership to 386,552 shares. On 09/09/2025 she sold 151 shares at $8.61, leaving 386,401 shares beneficially owned. The Form 4 was signed by an attorney-in-fact.
Arteris, Inc. (AIP) Form 144 notice reports a proposed sale of 2,278 common shares with an aggregate market value of $19,568.02. The shares represent part of the company's 42,649,917 outstanding common shares and are scheduled for sale on 09/09/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filer acquired these shares as Restricted Stock Units on 04/01/2025, with payment dated the same day. The filing also lists four secondary sales by the same person in the prior three months totaling 6,170 shares for gross proceeds of $65,374.37.
Arteris, Inc. (AIP) Form 144 reports a proposed sale of 3,660 common shares with an aggregate market value of $31,439.40, scheduled approximately for 09/09/2025 through NASDAQ by broker Morgan Stanley Smith Barney LLC. The shares were acquired as Restricted Stock Units from the issuer on 04/01/2025. The filing lists prior sales by the same person, Nicholas Hawkins, including multiple 10b5-1 plan transactions from 06/25/2025 through 09/02/2025 totaling several tens of thousands of shares and proceeds shown per trade.
Janac K Charles, President and CEO of Arteris, Inc. (AIP) and a director with 10% ownership, reported a planned sale of common stock executed on 09/04/2025 under a 10b5-1 trading plan adopted March 5, 2025. The reported transaction shows 2,057 shares sold at a weighted average price of $8.7255, with individual sale prices ranging from $8.5750 to $8.8900.
Following the sale, the reporting person beneficially owns 186,482 shares directly and indirectly holds 9,839,071 shares through Bayview Legacy, LLC and 56,252 shares through the Charles and Lydia Janac Trust. The filer provided the standard footnote offering to supply detailed per-price sale information on request.
Arteris, Inc. (AIP) Form 144: An insider intends to sell 424 shares of common stock through Morgan Stanley Smith Barney, scheduled approximately 09/08/2025, with an aggregate market value reported as $3,756.64. The filing reports those 424 shares were acquired as restricted stock units on 09/01/2025. The filing also discloses prior dispositions by the same person during the past three months: 258 shares on 09/02/2025 (gross proceeds $2,306.96) and two July sales totaling 6,488 shares (gross proceeds $59,259.89), including a 10b5-1 plan sale of 3,609 shares on 07/03/2025. The filer certifies no undisclosed material information.
Arteris, Inc. (AIP) filed a Form 144 reporting a planned sale of 12,978 common shares valued at $114,725.52, representing part of ~42.65 million shares outstanding, with an approximate sale date of 09/05/2025 on NASDAQ. The shares were acquired as restricted stock units on 09/01/2025 and are scheduled for sale the same month. The filing also discloses sales by Laurent Moll totaling 84,380 shares for aggregate gross proceeds of $915,838.75 over the past three months, including transactions executed under a 10b5-1 plan. The filer certifies no undisclosed material adverse information.
Arteris, Inc. (AIP) Form 4 summary: On 09/03/2025 the reporting person, Wayne C. Cantwell, filed changes in beneficial ownership showing related transfers of 228,198 shares of Arteris common stock. The Form records a 228,198 share disposition (code G(1)) reported at $0.00, and a corresponding 228,198 acquisition (code G) at $0.00 that is held indirectly by The Cantwell Living Trust. After the reported transactions, the filing shows 34,732 shares beneficially owned directly, 228,198 shares indirectly via The Cantwell Living Trust, and 38,761 shares indirectly by the Decathlon Capital Management 401K Plan FBO Wayne Cantwell. The form is signed by an attorney-in-fact on 09/04/2025.
Arteris, Inc. (AIP) submitted a Form 144 notifying the proposed sale of 2,057 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $18,163.31 and an approximate sale date of 09/04/2025. The shares were acquired as Restricted Stock Units on 09/01/2025. The filing also discloses multiple sales by the same account and related parties over the prior three months, including large 10b5-1 planned sales on 08/05/2025 and other dates. The filer attests there is no undisclosed material adverse information.